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A42-year-oldwomanpresented for recurrent episodes of diffuse ab-
dominal pain and, discomfort with increasing abdominal girth accom-
panied by heavy menses, urinary frequency and constipation. Her past
medical history is signiﬁcant for systemic lupus erythematosus. CT
scan and ultrasound of the abdomen and pelvis revealed bilateral
large solid adnexal masses associated with large amounts of free ﬂuid
in the abdomen and Douglas pouch. CA 125 antigen level was only
slightly elevated.
The patient underwent total hysterectomy with bilateral salpingo-
oophorectomy that showed an 11 cm × 8 cm right adnexal mass and
a 13 cm × 8 cm left mass, both with smooth bosselated intact surfaces
and ﬁbrous white-tan edematous cut surfaces oozing ﬂuid (Fig. 1).
Microscopic examination revealed a proliferation of spindled cells
with luteinized cells, prominent mitotic activity and entrapped cystic
follicles (Fig.2), diagnostic of luteinizing thecomas of the type typically
associated with sclerosing peritonitis (LTSP). Cytologic evaluation of
the abdominal ﬂuid revealed reactive mesothelial cells. No omental bi-
opsy was performed.⁎ Corresponding author.
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peritoneal manifestations. A CT scan showed increased peritoneal ﬂuid
with multi-loculated ﬂuid collections and the appearance of few small
pelvic lymph nodes. Initially these ﬁndings were interpreted as signs
of infectious peritonitis and antibiotics were administered. However,
the patients did not improve with antibiotics and infectious peritonitis
was ruled out by culture as well as cytologic examination of aspirated
peritoneal ﬂuid, which showed reactive mesothelial cells and no acute
inﬂammation. Another laparotomywas being considered, but the histo-
pathologic examination established the diagnosis of luteinizing
thecoma, and highlighted its known associationwith peritoneal lesions.
The diagnosis of sclerosing peritonitis was then considered in this con-
text. Subsequently, the patient was treated with Antiestrogen (Tamox-
ifen 20 mg PO QD), and GnRH agonist (Goserelin 3.6 mg s/c every
3 weeks for 3 months), Corticosteroids (Prednisone 30 mg PO BID)
and Proton Pump inhibitor. She improved signiﬁcantly and recovered
in a 2-month period, despite an episode of pulmonary embolism. The
patient was monitored periodically and was last seen in complete
remission, ﬁve years after her surgery.Fig. 1. Ovarian mass with edematous oozing cut surface.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Part of an entrapped cystic follicle (left upper corner) with cellular and hypocellular
areas of the lesion (H&E × 25).
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Ovarian thecoma is a rare ovarian sex cord stromal tumor. LTSP is a
rare variant of ovarian thecoma ﬁrst described in six patients in 1994
(Staats et al., 2008). Most thecomas are unilateral and range from
5 cm to 10 cm, while LTSP is usually bilateral and larger. Histologically,
the ovarian cortex is expanded by a proliferation of blandmitotically
active spindle cells with embedded clear to eosinophilic small lu-
teinized cells arranged in cellular areas alternating with edematous
areas including small capillaries with microscopic foci of hemor-
rhage. Typically, the lesion entraps preexisting ovarian follicles
(Staats et al., 2008).
Sclerosing peritonitis is a rare form of peritoneal inﬂammation
characterized by ﬁbrous thickening of the peritoneum involving
the visceral and parietal surfaces of the abdominal cavity. The
most common causes are peritoneal dialysis, certain drugs such an-
ticonvulsants, and infectious peritonitis. Sclerosing peritonitis asso-
ciated with luteinizing thecoma has been associated with more
complications than the one secondary to other diseases with higher
rates of re-laparotomies, intestinal resection and ﬁstula formation
(Bianco et al., 2005).
Staats et al. (2008) reported that, in 25 out of 27 patients with LTSP,
sclerosing peritonitis was diagnosed either intra-operatively or, in the
majority of patients, during follow-up. It has been hypothesized that
the ovarian lesion secretes ﬁbrogenic substances that cause sclerosis
of the peritoneum such as ﬁbrinogenic cytokines like TGF-βwhich is
believed to induce myoﬁbroblastic transformation of mesothelial
cells in peritoneal ﬁbrosis (Staats et al., 2008). However, the perito-
neal ﬁbrogenic process continues to progress after bilateral oopho-
rectomy in many of the patients, which make the exact cause of
sclerosing peritonitis unknown and not restricted to the factors
secreted by the ovarian lesion.
Although this tumor is benign, its outcomemaybe stern. In the review
of Staats et al., out of 27 cases, 3 patients died postoperatively, 10 sufferedpostoperative morbidities while the remaining 14 had a favorable out-
come. The prognosis of luteinized thecoma seems to be determined by
the evolution of the associated sclerosing peritonitis, which in most pa-
tients is not resolved with surgical resection of the ovarian tumors and
may induce additional surgical interventions that may cause signiﬁcant
complications and morbidities. Kim et al. suggested that the mortality
rate of dialysis related sclerosing peritonitis increased from 24%, without
treatment, to 60%, with surgical treatment due to surgery-associated
complications (Kim et al., 2005).
Due to the low incidence of LTSP, there has been no consensus on the
mainstay therapy. However, recent studies reported successful treat-
mentwithGnRH agonist, antiestrogen andhigh doses of corticosteroids.
Bianco et al. reported dramatic resolution of sclerosing peritonitis in a
39-year-old patient with LTSP after treatment with a combination of
GnRH agonist and antiestrogen (Kim et al., 2005). Mellembakken et al.
and Schonman et al. have also reported successful treatment with
GnRH agonist and high doses of corticosteroids in two young patients
with sclerosing peritonitis associatedwith LTSP,whobecame complete-
ly asymptomatic with fertility preservation (Mellembakken et al., 2010;
Schonman et al., 2008). Administering GnRH to a patient who has un-
dergone oophorectomy is controversial. However, some authors think
that luteinized thecoma is a nonneoplastic process induced by an exter-
nal stimulus that also affects the peritoneum. GnRH agonist may inhibit
such a stimulus, which may account for the reported successful treat-
ment of the peritoneal lesions that continue to progress even after
oophorectomy.
The clinical presentation of LTSP may be confusing and its diagnosis
challenging. Our case emphasizes that the recognition of this rare entity
and the awareness that LTSP may be successfully treated medically are
essential for the appropriate management of these patients and for
avoiding unnecessary and morbid surgeries.
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